Johnson and Johnson Gets CDSCO Panel Nod For Additional Indication of Daratumumab to Treat Light chain AL amyloidosis
New Delhi: Granting local clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved Johnson and Johnson's anticancer drug Daratumumab solution for Injection 1800 mg (120 mg/ml) for an additional indication for the treatment of Light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic AL amyloidosis.
Amyloidosis is a disorder of protein misfolding and metabolism in which insoluble fibrils are deposited in various tissues, causing organ dysfunction and eventually death.
Primary or light chain (AL) amyloidosis, the most common type of systemic amyloidosis, occurs when the free light chains normally associated with immunoglobulins are produced in excess by clonal or frankly malignant plasma cells. Although AL amyloidosis is not considered a cancer, it shares some similar characteristics and treatments with multiple myeloma.
Daratumumab is a CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found in some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells.
Daratumumab binds to CD38, causing cells to apoptosis via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer, or antibody-dependent cellular phagocytosis.
The committee observed that the treatment of Light chain (AL) amyloidosis comes under the orphan drug category. Furthermore, the expert panel highlighted that the applied indication for the treatment of Light Chain (AL) Amyloidosis is approved in the US, EU, Canada, Brazil, Switzerland, the UK, and China.
Also Read:Discontinue Olaparib Tablets Marketing For Specific Cancers: CDSCO
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.